14 results about "Activated coagulation factor" patented technology

This application relates to a preparation method of a protective three-dimensional structured hemostatic textile spacer fabric, and relates to the field of knitted medical dressings. In this application, the spacer dressing uses carboxymethyl-modified viscose filament-PTFE braided yarn as the skin contact material, and quickly stops bleeding through three methods: physical, chemical, and biological. The physical principle is to absorb blood to form a gel-like substance to block the wound. The chemical action concentrates the blood concentration to activate the coagulation system. The biological action releases negative ions to activate coagulation factors and initiate the endogenous coagulation system. Sodium carboxymethyl cellulose can be obtained by carboxymethylation modification of fibers, and PTFE plays a structural support role; Coolmax-nylon monofilament wrapping yarn with high water absorption and elastic recovery is used as the spacer filament; ultra-high molecular weight polyethylene fiber with superhydrophobicity is used as the outer surface material, and the surface structure is tight to play a barrier role; furthermore, a preparation method of a protective three-dimensional structured hemostatic textile spacer fabric is designed.

A pharmaceutical composition comprising blood coagulation factor X for use in the treatment of a subject having hemophilia type A is provided. The present invention relates to a pharmaceutical composition, which is a pharmaceutical composition comprising blood coagulation factor X for use in the treatment of a subject having hemophilia type A wherein the blood coagulation factor X is used in combination with a bispecific antibody that binds to activated blood coagulation factor IX and blood coagulation factor X.

The invention relates to a high purity Coagulation Factor Xa (FXa or activated Coagulation Factor X) preparation and an activation and purification process to obtain said FXa of high purity and high degree of activation without addition of proteinaceous activators during manufacturing.

The invention relates to a high purity Coagulation Factor Xa (FXa or activated Coagulation Factor X) preparation and an activation and purification process to obtain said FXa of high purity and high degree of activation without addition of proteinaceous activators during manufacturing.

The present invention relates to the preparation of high-purity coagulation factor Xa (FXa or activated coagulation factor X) and an activation and purification method for obtaining the high-purity and highly activated FXa, which does not require the addition of a protein activator during the preparation process.

The utility model discloses a soluble hemostatic gauze bandage, belonging to the technical field of medical supplies. The technical scheme thereof includes a substrate layer, a liquid absorbing layer is arranged on the top of the substrate layer, and a hemostatic layer is arranged on the top of the liquid absorbing layer. The substrate layer includes a bottom base layer, an isolation layer is arranged on the top of the bottom base layer, and a connecting layer is arranged on the top of the isolation layer. The hemostatic layer can be quickly dissolved into a highly adhesive jelly after contacting with a bleeding wound surface, effectively covering and blocking damaged capillaries, and at the same time, the blood is concentrated and coagulation factors are activated, thereby achieving the effect of effectively shortening the coagulation time, thereby reducing the pain of nerve endings, and can also effectively prevent adhesion when replaced. At the same time, the liquid absorbing layer can be used in conjunction with the liquid absorbing layer, and the liquid absorbing layer can absorb a large amount of blood or exudate to avoid wound infection and improve the use effect.

An objective of the present invention is to provide an effective pharmaceutical composition or a dosage regimen for preventing and / or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors discovered that by administering a pharmaceutical composition comprising a bispecific antigen-binding molecule that recognizes (a) blood coagulation factor IX and / or activated blood coagulation factor IX and (b) blood coagulation factor X and / or activated blood coagulation factor X according to a given dosage regimen, bleeding, a disease accompanying bleeding, or a disease caused by bleeding can be prevented and / or treated more effectively.

Provided is a pharmaceutical composition for treating a subject receiving treatment with a direct oral anticoagulant targeting activated blood coagulation factor X. This pharmaceutical composition contains activated blood coagulation factor VII and blood coagulation factor X and is for treating a subject receiving treatment with a direct oral anticoagulant targeting activated blood coagulation factor X.

To provide a multi-specific antigen-binding molecule having an alternative function to the function of blood coagulation factor VIII.SOLUTION: The present invention provides a multi-specific antigen-binding molecule with high activity substituting for the function of blood coagulation factor VIII. The molecule is found out among various prepared bispecific antibodies each specifically binding to both the blood coagulation factor IX / activated blood coagulation factor IX and the blood coagulation factor X and having an alternative function to the cofactor function of the blood coagulation factor VIII, i.e., the function of promoting the activation of the blood coagulation factor X by the activated blood coagulation factor IX.SELECTED DRAWING: None

This invention discloses a gelatin-based hemostatic powder with high osmotic pressure properties and its preparation method. The hemostatic powder is a porous gelatin-based material grafted with high-osmotic-pressure anionic functional groups such as sulfonic acid groups or their derivatives. The sulfonic acid groups or their derivatives endow the hemostatic powder with negative charge and high osmotic pressure properties, thereby achieving a dual hemostatic effect of osmotic pressure-driven blood concentration and negative charge enrichment to activate coagulation factors. The strong dissociation properties of the sulfonic acid groups or their derivatives endow the material with a surface negative potential of -20 to -50 mV and a high osmotic pressure of 0.30 to 0.55 Osmol / kg, achieving a pressure of 40 to 60 g·g. ‑ ¹ water absorption ratio and 0.15–0.20 g·g ‑ ¹·min ‑ ¹ Rapid water absorption. The preparation method of this invention involves activating the carboxyl group of gelatin and grafting a functional monomer containing a primary amino group, followed by purification, freeze-drying, and grinding. This invention achieves dual hemostatic effects of osmotic pressure-driven blood concentration and negatively charged enrichment to activate coagulation factors, making it suitable for wound hemostasis of arterial, venous, and organ bleeding.

This invention discloses the use of substances that interfere with the expression of coagulation factor X (F10) or inhibit the activity of its activated form, activated coagulation factor X (FXa), in the preparation of drugs for the prevention or treatment of abdominal aortic aneurysm (AAA), belonging to the field of biomedicine. This invention is the first to discover that endothelial-derived F10 / FXa is significantly upregulated in the early stages of AAA development. FXa can disrupt the stability of the endothelial tight junction protein ZO-1 through a non-coagulation-dependent pathway, driving vascular barrier dysfunction and AAA progression. In vivo experiments have confirmed that inhibiting F10 expression or FXa activity can significantly reduce the AAA tumorigenesis rate and inhibit aortic dilation, providing a novel target and intervention strategy for the early prevention and drug treatment of AAA.

The invention relates to a composite sponge based on calcium silicate biological ceramic and a preparation method and application thereof, St-Nor and HS-PEG-SH are prepared into a polymer precursor solution, a proper amount of modified anion polysaccharide-sodium alginate is introduced, then the prepared CS is added into the polymer solution, and after foaming treatment, cross-linking curing and freeze drying, the composite sponge based on calcium silicate biological ceramic is obtained. A series of composite sponges based on calcium silicate biological ceramics are obtained, the composite sponges not only have good water absorption capacity and rapid shape recovery capacity, but also have relatively strong mechanical properties, have the potential of expandable hemostatic sponges in incompressible and massive hemorrhage applications, have relatively strong water absorption capacity and macroporous structures, and are suitable for large-scale popularization and application. When the sponge is in contact with blood, blood components such as blood platelets and red blood cells can be effectively enriched, and meanwhile, CS in the sponge plays an important role in accelerating the blood coagulation process. The negative charges in the sponge activate the blood coagulation factor XII and thrombin to trigger the blood coagulation cascade rapid reaction, and further enhance the thrombus strength through the interaction with fibrinogen, so that the sponge has an enhanced hemostatic effect in a massive hemorrhage model and a massive hemorrhage model in a blood dilution state.

A double-network structure sponge material and its preparation method and application, construct a double-network structure, improve the mechanical strength and procoagulant activity of the sponge, and show a significantly improved hemostatic effect at a specific ratio. It still maintains excellent mechanical properties in the fully swollen state, can enhance the strength of the blood clot, and at the same time, can directly activate coagulation factor XII, increase thrombin activity, and show a high procoagulant ability. The 3D printability of the sponge under this formula was verified by DIW and freeze-drying technology, and customized porous sponges with excellent mechanical properties and enhanced procoagulant potential were printed. It is a very promising hemostatic material for the treatment of acute bleeding. The proposed 3D printing strategy for hemostatic sponges will change its processing method and provide the possibility for personalized customization and manufacturing of complex hemostatic materials.

An objective of the present disclosure is to provide effective pharmaceutical compositions and dosage regimens for preventing and / or treating bleeding, a disease accompanying bleeding, or a disease caused by bleeding. The inventors found that categorized flat dosing (CFD) of emicizumab can provide therapeutic effects and safety that are comparable with those of per-kg dosing (PKD), as well as more simplified, less wasteful regimens and enables administration with injectable device such as an autoinjector or syringe.